Segmed Appoints David Gascoigne as CEO Amid Leadership Changes

Segmed has appointed David Gascoigne as its new Chief Executive Officer, announced in a press release. This leadership transition also sees co-founder Dr. Martin Willemink moving to the role of Chief Scientific Officer, while Dr. Yin Ho joins the Board of Directors.

David Gascoigne brings over 30 years of experience in healthcare, life sciences, and AI, having previously served as CEO of Almaden Genomics. His appointment comes as Segmed aims to expand its reach and innovation in medical imaging and AI-driven healthcare solutions.

Dr. Martin Willemink, who has led Segmed through significant growth and funding rounds, will now focus on advancing the company's scientific vision and market presence. Meanwhile, Dr. Yin Ho, with her extensive background in healthcare IT and clinical research, will contribute strategic insights as an Independent Director.